Venus inaugurates its Medicine Research Centre

Venus Remedies Ltd has informed that the Company has Inaugurated the Sixth and last phase of its INR 150 Crore expansion Project, its state of the art and hi-tech and elaborate Research facility, "Venus Medicine Research Centre" at its Baddi Campus on January 14, 2008.

This new R&D Centre, which has been set up with an investment of approx. INR 250 million, is spread over 40,000 sq. feet built up area in the Baddi Campus of the Company. It is proposed to be driven by a team of 50 intellectuals, including 25 scientists, Pharmacists, Chemists, Analysts and technicians.

The Centre has 7 dedicated pilot plants, built as per latest international standards for conducting trial production of Injections in Super specialty segments and eight fully equipped laboratories to cater for all kinds of Testing in-house. This R&D centre will further strengthen the Research capabilities of the Company and help in building a stronger pipe line of solutions for diseases for which there is no treatment as on date.

The Company plans for accreditation of this Center with the Department of Science and Technology, Government of India as well as securing other certifications to build the Intellectual wealth of the Company.

With this inauguration, the Company is through with its 6 phase expansion program started in April 2005. In the last 33 months, the Company has created sufficient infrastructure to meet its target for 2010 with the setting up of Eight new dedicated manufacturing plants for injectible at Baddi duly accredited by European GMP, ISO 9001, 14001 and 18001 and numerous other international Quality certifications and a modern Research Centre at Baddi Campus and one infusion manufacturing unit at Panchkula, all built as per international benchmark. The Company is now ready to venture in overseas market with its EU-GMP certified facilities and innovative products.

Venus Remedies gains European GMP certification

Venus Remedies Ltd has informed that the Company has been accredited with the European GMP certification for its Cephalosporin and Carbapenem plants at Baddi, India, a rare and most coveted certification for regulated markets.

The Cephalosporin and Carbapenem Plants of the Company were inspected by the European authorities and found to be complying with the Manufacturing and Quality Control Standards as per the European Good Manufacturing Practice.

The European - GMP certification is a pre-requisite for Export to European Union. With this accreditation, the Company can now freely export to not only 36 countries of European Union, but also to Canada and Australia, which recognize European GMP. Now the Company can surge ahead in the regulated European and Canadian markets, as per its strategy, in sync with its subsidiary Venus Pharma GmbH, Germany and realize its export targets as per projections. The Company has already entered into Product Development, Manufacturing and Marketing agreements with leading Multi National Companies from Europe for its specialty Anti-biotic range in the Cephalosporin and Carbapenem segments. Negotiations are underway for similar agreements with leading players of Canadian market.

Venus is the only Company in India to have an EU-GMP certified plant for Carbapenems, which the have huge market potential across the globe. This certification has further fortified the foundation for Company's expansion plans and cleared the path to its international foray in regulated markets in a big way

Venus Remedies - National phase filing completed for 5th PCT

Venus Remedies Ltd has informed that maintaining its pace of IP creation, Venus's IPR Wing has successfully filed for Patent protection for Company's 5th Research Product, "Treatment and Control of severe infections, including Cystic Fibrosis" in 47 countries around the globe where the product is planned to be launched by the Company.

This revolutionary antibiotic, a Fixed Dose Combination, was developed by the Research and Development wing of the Company as a premium solution for multi-resistant strains of bacteria, especially in Cystic Fibrosis patients. The Indian Patent for the same is under process since June 2005 while the National Phase of the PCT application has been completed with the filing of Patent applications in 47 selected countries having good potential market for the product. These include regulated markets like USA, Brazil, entire European Union, Australia, New Zealand and Japan.

The International Regulatory Affairs Department of the Company will be filing dossiers for
Product registration in these countries for market authorizations and the product will be
launched in international market worth USD 500 million, for the first time globally, by the Company.

Venus Remedies files for patent on its research report

Venus Remedies Ltd has informed that the Company has successfully filed for Patent protection for its 4th Research Product, "Parenteral Combination Therapy for infective conditions with Drug Resistant Bacterium" in 48 countries across the globe, completing the National Phase of the 4th PCT well within the timeline.

The in-house Research and Development wing of the Company had developed this innovative remedy, a Fixed Dose Combination, as the only solution for treatment of Meningitis. The same was launched for the first time globally in Indian Market in October 2005 under Strategic Marketing Tie-ups with leading Indian MNCs, after filing for Indian Patent. The high-end niche product has fast penetrated the market for specialty formulations and grown to be an INR 250 million brand within 2 years of its launch.

The Company has selected 48 countries with high marketing potential for this product in a world market worth USD 900 million, including Australia, Brazil, Canada, China, E.U, New Zealand and USA, being major ones amongst the total.

Venus Remedies patent update

Venus Remedies Ltd has informed that the filing of Patent in individual countries of selection under the National Phase of PCT application for the third research product of Venus Remedies Ltd has been successfully completed in 48 countries for worldwide protection of the innovation in Patent 3 i.e. "Fixed Dose Combination of a latest generation Cephalosporin with an Aminoglycoside".

The Indian Patent for this innovative solution for treatment of life threatening infections caused by multi resistant P.aeruginosa or Acinetobactor species and / or MRSA was filed in December 2004 and the PCT in December 2005. The Company selected 48 countries with good market potential in the National Phase of the PCT application for global Patent, including entire Europe, USA, Brazil, Japan, Canada, Australia and New Zealand, where it would be registering and launching this product.

The product was launched in domestic market in October 2006 and is fast growing to be one of the leading multi-specialty, Critical Care brands. The potential market for this product across the globe is estimated to be around USD 1.00 billion.

Venus Remedies Limited

Venus Remedies Limited has informed the Exchange that: "Venus Remedies Limited has got success in getting another of its Research Product, a FDC of Cephalosporin with an Amino-glycoside, registered in Ukraine and got regulatory approval for selling in this market".

Venus Remedies

Sonata Investments has acquired 1.72% of the total Equity on 31-Aug-2007

Their total investment in Venus Remedies is now 11.17